D. Mercuri

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

Efficiency analysis of a sliding-mode controlled quadratic boost converter

Luis Martinez-Salamero, Hugo Valderrama-Blavi, Daniel O. Mercuri, 2013 .